180 Life Sciences Corp

For the period ended Dec 31, 2023. Filed Mar 25, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 25, 2024

FRMM$2.82-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

	For the Year Ended
	December 31,
	2023	2022
Operating Expenses:
Research and development	$2,303,751	$2,191,834
Research and development - related parties	480,777	240,731
General and administrative	10,646,417	15,459,788
General and administrative - related parties	46,555	5,612
Total Operating Expenses	13,477,500	17,897,965
Loss From Operations	(13,477,500)	(17,897,965)
Other Income (Expenses):
Other income	21,074	-
Interest expense	(44,828)	(28,175)
Interest income – related parties	-	1,508
Loss on goodwill impairment	-	(33,547,278)
Loss on IP R&D impairment	(9,063,000)	(3,342,084)
Change in fair value of derivative liabilities	75,323	15,144,986
Gain on settlement of accrued liability	204,405	-
Total Other Expense, Net	(8,807,026)	(21,771,043)
Net Loss Before Income Taxes	(22,284,526)	(39,669,008)
Income tax benefit	2,349,414	942,749
Net Loss	$(19,935,112)	$(38,726,259)
Other Comprehensive Loss:
Foreign currency translation adjustments	(15,816)	(3,702,963)
Total Comprehensive Loss	$(19,950,928)	$(42,429,222)
Basic and Diluted Net Loss per Common Share	$(52.59)	$(387.18)
Weighted Average Number of Common Shares Outstanding:	379,089	100,021

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.